Literature DB >> 7544215

Prostatic growth: new insights into hormonal regulation.

J D McConnell1.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7544215

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


× No keyword cloud information.
  26 in total

Review 1.  The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

Authors:  Jaspreet S Sandhu; Alexis E Te
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

Review 2.  Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.

Authors:  Jaspreet S Sandhu; E Darracott Vaughan
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

4.  Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.

Authors:  Luis Alberto Henríquez-Hernández; Almudena Valenciano; Palmira Foro-Arnalot; María Jesús Álvarez-Cubero; José Manuel Cozar; José Francisco Suárez-Novo; Manel Castells-Esteve; Pablo Fernández-Gonzalo; Belén De-Paula-Carranza; Montse Ferrer; Ferrán Guedea; Gemma Sancho-Pardo; Jordi Craven-Bartle; María José Ortiz-Gordillo; Patricia Cabrera-Roldán; Estefanía Herrera-Ramos; Carlos Rodríguez-Gallego; Pedro C Lara
Journal:  J Genet       Date:  2015-06       Impact factor: 1.166

5.  Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.

Authors:  Yasuhito Funahashi; Katherine J O'Malley; Naoki Kawamorita; Pradeep Tyagi; Donald B DeFranco; Ryosuke Takahashi; Momokazu Gotoh; Zhou Wang; Naoki Yoshimura
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

6.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

7.  Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems.

Authors:  Ryan Tasseff; Satyaprakash Nayak; Saniya Salim; Poorvi Kaushik; Noreen Rizvi; Jeffrey D Varner
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

8.  Therapeutic options in the treatment of benign prostatic hyperplasia.

Authors:  Jaspreet S Sandhu
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.